Previous studies also indicated that lenvatinib could strongly inhibit the activation of ERK, the downstream signaling molecules of FGFR4, compared with sorafenib and regorafenib [32], and high FGFR4 levels (positive immunohistochemistry >10% of tumor cells) were an independent predictor of a response to lenvatinib [33]. This evidence concerns the gene FGFR4 and neoplasm.